Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model
Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model
复制标题
DOI:
10.1016/j.neulet.2008.11.059
复制
发表时间:
2009-01-30
影响因子:
2.5
通讯作者:
Bae, Jae-sung
中科院分区:
文献类型:
--
作者:
Lee, Jong Kil;Jin, Hee Kyung;Bae, Jae-sung
The therapeutic potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) has recently been explored in various pathological conditions of the central nervous system (CNS). However, the application of BM-MSCs in acutely induced Alzheimer's disease (AD) has not yet been reported. Herein the feasibility of using the BM-MSCs, as a therapeutic agent for AD has been tested. To assess this possibility, an acutely induced AD model induced by injecting amyloid-beta (A beta) into the dentate gyrus (DG) of hippocampus of C57BL/6 mice was used. Intracerebral transplantation of BM-MSCs into the brain of an induced AD model reduced their A beta levels when compared to sham-transplanted animals. The diminution of A beta deposits was accompanied by the activation of microglia. In addition, the activated microglia was located near the A beta deposits, and their morphology was changed from ramified to ameboid as a sign of microglial phagocytosis. This study provides evidence that BM-MSCs can promote the reduction of A beta through the microglial activation in this acutely induced AD brain, suggesting a potential therapeutic agent against AD. (C) 2008 Elsevier Ireland Ltd. All rights reserved